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Aims: To review literature describing factors associated with receipt of chemotherapy for breast 
cancer, to better understand what factors are most relevant to women’s health and whether health 
disparities are apparent, and to assess how these factors might affect observational studies and 
outcomes research. Patterns of care for metastatic breast cancer, for which no standard-of-care 
exists, were of particular interest.
Methods: Relevant studies written in English, Italian, French, or Spanish, published in 2000 
or later, were identified through MEDLINE and reviewed. Review articles and clinical trials 
were excluded; all observational studies and surveys were considered. Articles were reviewed 
for any discussion of patient characteristics, hospital/physician/insurance characteristics, 
psychosocial characteristics, and clinical characteristics affecting receipt of chemotherapy by 
breast cancer patients.
Results: In general, factors associated with increased likelihood of receiving chemotherapy 
included younger age, being Caucasian, having good general health and few co-morbidities, 
having more severe clinical disease, having responded well to previous treatment, and having 
breast cancer that is estrogen- or progesterone-receptor-negative. Many of the clinical factors 
found to increase the likelihood of receiving chemotherapy were consistent with current oncology 
guidelines. Of the relevant 19 studies identified, only six (32%) reported data specific to metastatic 
cancer; most studies aggregated women with stage I–IV for purposes of analysis.
Conclusion:  Studies of patterns of care in breast cancer treatment can help identify challenges 
in health care provided to particular subgroups of women and can aid researchers in designing 
studies that account for such factors in clinical and outcomes research. Although scarce, studies 
evaluating only women with metastatic breast cancer indicate that factors affecting decisions 
related to receipt of chemotherapy are similar across stage for this disease.
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Introduction
As the most common cancer affecting American women, significant research effort and 
resources have been dedicated to the prevention, control, and treatment of breast cancer. 
Since 2003, breast cancer research accounts for the highest proportion of appropriated 
National Cancer Institute (NCI) funds for an individual cancer.1 Despite these efforts, 
however, breast cancer remains a poorly understood disease and a significant cause of 
morbidity and mortality among American women. For the estimated 192,000 American 
women who will develop breast cancer in 2009,2 factors affecting their prognosis and 
survival from disease are of utmost importance. Therefore, the need continues for 
breast cancer research and public health education and outreach programs.International Journal of Women’s Health 2010:2 108
Morimoto et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Observational studies play an important role in studies 
of treatment effectiveness and survival, and can play a role 
in optimizing the use of therapeutics. Compared to clinical 
trials, they are able to quantify rarer events over longer peri-
ods of time and can provide a “real-world” picture of drug 
efficacy and safety in actual usage outside the trial setting. 
However, observational studies, like other research formats, 
are susceptible to potential biases from misclassification, 
differential selection, confounding, and incomplete adher-
ence. Studies examining patterns of care in cancer treatment, 
therefore, provide valuable information for researchers that 
can affect the outcome and interpretation of results.
For breast cancer, late-stage and metastatic breast cancer 
treatment patterns are particularly difficult to study. Although 
only 6% of patients have metastatic/stage IV disease at diag-
nosis,3 10% to 40% of women with early-stage breast cancer 
will eventually develop distant disease and metastases.4,5 For 
these women, there is no standard-of-care guideline, and 
complex treatment decisions are based on individual patient 
and tumor characteristics. The goal is generally to manage 
symptoms and prolong life, rather than to cure the disease. 
Recommended treatment for incident or recurrent stage IV 
breast cancer may include surgery, hormone therapy, aroma-
tase inhibitors, ovarian ablation or suppression, therapeutic 
or palliative chemotherapy, or supportive care, depending 
on the patient’s prior treatments (radiation, surgery, anties-
trogens, previous chemotherapy), tumor hormone receptor 
status, physical health, and menopausal status.6 For many 
of these, decisions are made primarily on the basis of clini-
cal status, as is called for in typical oncology guidelines. 
Patients’ preferences for treatment have become increasingly 
important in clinical decision making, and factors such as 
trade-offs between quantity and quality of life, and patient 
hopes, expectations, values, and priorities, are weighed.7 
With each progressive step of planning a patient’s care, 
numerous selection factors are introduced that can affect 
receipt of treatment.
In addition to patient preferences, some factors beyond a 
patient’s control can dictate whether they are treated with che-
motherapy for late-stage disease. Health disparities in cancer 
outcomes and treatment have been well documented, and 
addressing the causes and establishing measures to mitigate 
these differences have become increasingly higher priorities 
of government health care program policies.8–10 Cancer health 
disparities, frequently marked by age, race/ethnicity, income, 
educational attainment, or geographic location,9 are reflected 
in differences in cancer incidence, mortality, and survival 
rates across groups and are thought to be due to disparities in 
access to health care, which affects screening rates, treatment 
resources, and the quality of treatment given.11 Therefore, 
the decision to treat with chemotherapy for breast cancer 
may also be influenced by a woman’s inability to receive 
treatment if desired, as well as by lack of knowledge about 
the treatment options available to her.
Factors affecting the receipt of chemotherapy in women 
with breast cancer have been well studied, but no literature 
currently exists that compiles factors associated with patient 
characteristics, hospital/physician/insurance characteristics, 
psychosocial characteristics, and clinical characteristics in a 
single source. For example, it is commonly understood that 
older women are generally less likely to receive chemo-
therapy due to the shorter life expectancies of older women, 
general poorer health, and the reduced risk/benefit; however, 
other factors may also influence receipt of chemotherapy, 
even in younger women, and need to be accounted for in 
observational studies and outcomes research involving breast 
cancer. In addition, quantifiable information on specific 
influences of palliative treatment of metastatic breast cancer 
is particularly scarce. Therefore, we performed a review of 
the literature and information published since 2000 regard-
ing the factors affecting decision making for the receipt of 
chemotherapy in patients with breast cancer, particularly 
metastatic cancer, taking into account patient characteristics, 
hospital/physician/insurance characteristics, psychosocial 
characteristics, and clinical characteristics.
Methods
Literature search and review
A MEDLINE search was performed using the following 
query: breast cancer AND (recurrent OR metastatic 
OR advanced stage OR advanced disease OR stage IV OR 
stage I OR stage II or stage II or early stage OR early dis-
ease) AND (chemotherapy OR treatment OR second line OR 
third line) AND (practice patterns OR health services OR 
decision-making OR predictors OR disparity OR correlates 
OR quality of life) NOT (“review” [Publication Type]) NOT 
(“clinical trial” [Publication Type]) NOT (“case reports” 
[Publication Type]). Searches were limited to the year 
2000 or later. Review articles, case reports, and clinical trials 
were excluded; observational, clinical, and population-based 
studies were considered, as were survey data of physicians 
and oncologists. General clinical reviews that provided treat-
ment guidelines but no original data were also excluded. This 
initial search returned 491 studies discussing chemotherapy 
and breast cancer, of which 46 were deemed relevant for 
further review based on criteria that were set a priori by the International Journal of Women’s Health 2010:2 109
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contributing authors and as containing information related to 
the four categories of interest (patient characteristics, hospital/
physician/insurance characteristics, psychosocial characteris-
tics, and clinical characteristics). The bibliographies of these 
studies, as well as those of several recent review articles, 
were also reviewed, and an additional 35 articles of potential 
relevance were identified. All articles were reviewed by one 
or more authors; studies were excluded from our discussion if 
they specifically excluded cases of metastatic breast cancer, if 
they did not include information regarding chemotherapy as 
a treatment, or if they contained only data on the differences 
in response to (not receipt of ) chemotherapy. Thus, articles 
identified spanned receipt of chemotherapy treatment in 
stage I–IV breast cancer patients.
Using the above criteria, of the 81 articles reviewed, 19 were 
identified as pertinent to treatment decision-making in breast 
cancer (either specific to or including stage IV) and chemo-
therapy,12–30 and 62 were excluded. Of the 19 studies, only six 
provided data specific to metastatic (stage IV) disease.13,18,19,21–23 
One of these22 reported tabular data for “metastatic” breast 
cancer, but discussed the cases as “advanced” breast cancer 
in the text. For the purposes of this paper, we considered the 
data to be specific to metastatic disease. Most of the studies 
were conducted in populations in the United States12,15,17,18,23–29 
and the United Kingdom.16,20,22,30 Studies from other countries 
included one from France19 and one from Australia.13
The factors studied in relation to receipt of chemotherapy 
were roughly divided into four primary categories: patient 
characteristics, hospital/physician/insurance characteristics, 
psychosocial characteristics, and clinical characteristics. 
Some studies spanned more than one factor. Of the 19 studies 
identified as relevant, 15 mentioned patient characteristics, 
including demographic characteristics such as age, race, 
marital status, socioeconomic status (SES), and education. 
Four mentioned hospital/physician/insurance characteristics 
such as insurance status, physician type, and type of medical 
facility, while five mentioned psychosocial characteristics, 
including patient anxiety and depression. Finally, seven stud-
ies mentioned clinical characteristics such as tumor mark-
ers, lymph-node involvement, type of previous treatment, 
response to previous treatment, patient general health, and 
the presence of co-morbidities. Our findings for each factor 
are summarized individually in the following sections.
Results
Patient characteristics
Patient characteristics evaluated in the studies identified 
included age, race, SES/income, education, and language 
barriers (Table 1). Age was the most frequently considered 
characteristic, being discussed in 10 studies.14,15,17–20,22,26,28,30 
Race was considered in five studies,12,18,25,26,29 SES/income in 
three,12,16,24 education in four,12,22,26,28 and language barriers 
in two.12,22
Age
All of the studies identified found that older women 
received chemotherapy less commonly than did younger 
women.14,15,17–20,26,28,30 Of these studies, seven provided 
numerical data to support this conclusion (Table 1).15,17–20,28,30 
Five of the studies demonstrated a statistically significant 
difference in chemotherapy use between older and younger 
women,17–20,28 although only two of these provided data spe-
cific to metastatic breast cancer.18,19 In a prospective survey 
of qualified specialists in France, the authors noted that, of 
the women receiving chemotherapy, 82% in the younger age 
group received the standard dose and cycle length, but only 
62% of those in the older age group received it (P  0.01).19 
Odds ratios (ORs) were presented from the Surveillance 
Epidemiology and End Results (SEER)-Medicare-linked 
database of women with breast cancer diagnosed in 1991 and 
1992, where the odds of receiving chemotherapy among US 
women with Medicare claims decreased with increasing age 
as 0.60 (95% confidence interval [CI]: 0.51–0.70), 0.33 (95% 
CI: 0.27–0.40), and 0.11 (95% CI: 0.0–0.14) for women 
aged 70–74, 75–79, and 80 years and older, respectively, 
relative to women aged 65–69 years. Among women with 
stage IV disease, the proportion with Medicare claims for 
chemotherapy decreased from 39% among women between 
the ages of 65 and 69 years to only 10% among women 80 
years of age or older.18 In a survey administered to medical 
and clinical oncologists in the UK, asking which factors were 
important in deciding whether to recommend chemotherapy 
to patients with metastatic breast cancer, patient age was 
considered to be “quite important” or “very important” for 
58.6% of oncologists surveyed.22
Several studies offered reasons to explain why older 
women received chemotherapy less often. Commonly 
cited reasons included little clinical evidence to prove the 
benefit of chemotherapy in older women,30 the shorter 
life expectancies of older women and the reduced cost/
benefit,28–31 and having fewer incentives (eg, dependents) 
to invest in therapies that may extend their lives.28 The 
lower proportion of older women with breast cancer receiv-
ing chemotherapy may also reflect an increased number 
of co-morbidities and worse general health among these 
women.19 For example, among British oncologists, “frailty” International Journal of Women’s Health 2010:2 110
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Table 1 Studies related to the role of patient characteristics in treatment decision making for breast cancer
Reference  Number of  
subjects in study
Percent of patients  
receiving chemotherapy
Odds ratio  Comment 
Age
Caban et al14 n = 234 Patient age was a  
significant predictor  
of neoadjuvant therapy
— Data not shown  
Study included stages I−Iv
Diab et al15 n = 50,828 (San Antonio  
breast cancer databases)  
n = 256,287 (Seer)
55−64 years: 30  
65−74 years: 16  
75−84 years: 6  
85 years: 1
— Study included stages I−Iv
Du and  
Goodwin17
n = 10,604  
– 65−69: n = 2,893  
– 70−74: n = 2,901  
– 75−79: n = 2,280  
– 80: n = 2,530
65−69 years: 39  
80 years: 10
— Information is specific  
to stage Iv disease
— Odds of receiving  
chemotherapy relative to  
65−69 year olds:  
70−74 years: 0.60  
(95% CI: 0.51−0.70)  
75−79 years: 0.33  
(95% CI: 0.27−0.40)  
80 years: 0.11  
(95% CI: 0.08−0.14)
Information includes stages 
I–Iv
Du and  
Goodwin18
n = 35,060  
(no age-specific n’s given)
65−69 years: 21  
70−74 years: 14  
75−79 years: 9  
80+ years: 3
Odds of receiving  
chemotherapy relative to  
65−69 year olds:  
70−74 years: 0.55  
(95% CI: 0.50−0.60)  
75−79 years: 0.29  
(95% CI: 0.26−0.32)  
80+ years: 0.08  
(95% CI: 0.07−0.09)
Study included stages I−Iv
Freyer et al19 n = 1,009  
– 65−74: n = 500  
–  75: n = 509
65−74 years: 50  
75 years: 28
— Study included only stage Iv 
cases  
reported P-value 0.001
Percentages receiving the  
standard dose and  
cycle length:  
65−74 years: 82  
75 years: 62
— Study included only stage Iv 
cases  
reported P-value 0.01
Golledge et al20 n = 784  
– 50: n = 181  
– 50–59: n = 171  
– 60–69: n = 179  
– 70–79: n = 143  
– 80: n = 110
Lymph node positive  
cases:  
50 years: 58  
50−59 years: 36  
60−69 years: 11  
70−79 years: 3  
80 years: 6
— —
Lymph node negative  
cases:  
50 years: 30  
50−59 years: 7  
60−69 years: 1  
70−79 years: 1 
80 years: 0
— P-value compares the age  
groups 60 years and  
60 years  
reported P-value 0.0001  
Study includes stages I−Iv
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Table 1 (Continued )
Reference  Number of  
subjects in study
Percent of patients  
receiving chemotherapy
Odds ratio  Comment 
Grunfeld et al22 n = 30 oncologists — — Surveyed for stage Iv 
treatment only  
Authors reported that 
58.6% of clinicians rated age 
as quite or very important 
in decision to give pallitive 
chemotherapy
Mitchell et al26 n = 682 Older age was a  
significant predictor  
of belief in religious  
intervention in place  
of treatment (r2 = 0.11)
— Study interviewed  
cancer-free women about 
  hypothetical breast cancer 
experiences  
reported P-value 0.0001
Peele et al28 n = 386 Younger patients were  
more likely to choose  
adjuvant therapy
— Study included stages I−Iv 
reported P-value of 0.006
Wyld et al30 n = 378  
Age group  
– 55–69: n = 210  
– 70: n = 167
55−69 years: 32.0  
70 years: 0.01
— Study included stages I−Iv
Race
Ashing-Giwa  
et al12
n = 102  
– African-American: n = 24  
– Asian: n = 34  
– Latina: n = 26  
– Caucasian: n = 18
African Americans  
were the least likely  
to have received  
adjuvant therapies,  
including chemotherapy
— Data not shown  
Interviews with cases  
in stages I–Iv
Du and  
Goodwin17
n = 10,604  
– White: n = 9,754  
– Black: n = 540  
– Other: n = 310
White: 26.5  
Black: 26.8  
Other: 18.2
— Information is specific to 
stage Iv disease
— Odds of receiving  
chemotherapy relative  
to white patients:  
Black: 0.93 (95% CI: 0.70−1.23)  
Other: 0.66 (95% CI: 0.43−1.10)
Information includes stages 
I–Iv
Maloney et al25 n = 52  
– African-American: n = 36  
– Caucasian: n = 16
Caucasian: 81.3  
African American: 80.0
— Study included stages I−Iv 
reported P-value 0.92
Mitchell et al26 n = 682  
– African-American: n = 280  
– White: n = 402
Being African American  
was a significant predictor  
of belief in religious  
intervention in place  
of treatment (r2 = 0.41)
— Study interviewed  
cancer-free women about 
hypothetical breast cancer 
experiences  
reported P-value 0.001
Shavers et al29 n = 3,978  
– African-American: n = 724 
– Hispanic: n = 616  
– Non-Hispanic white: n = 2,638
African American: 46.5  
Hispanic: 52.4  
Non-Hispanic white: 67.0
— Study included stages I−Iv
SES/Income
Ashing-Giwa et al12 n = 102 — — Interviews with cases  in 
stages I–Iv  
Authors observed that 
women with lower SeS lack 
awareness regarding the 
disease, resources, and treat-
ments, and are not proactive 
about seeking medical care
(Continued )International Journal of Women’s Health 2010:2 112
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Table 1 (Continued)
Reference  Number of  
subjects in study
Percent of patients  
receiving chemotherapy
Odds ratio  Comment 
Downing et al16 n = 12,768 Quartile I (affluent): 29.2  
Quartile II: 28.7  
Quartile III: 28.2  
Quartile Iv (deprived): 26.4
— Study included stages I−Iv 
Authors reported that 
results were “not significant”
Liu et al24 WHN: n = 331 (lower income)  
Other in MA state:  
n = 13,372
Lower income: 35.4  
Overall: 37.2
— Study included stages I−Iv  
Numbers also reported  
under Insurance Status
Education
Ashing-Giwa et al12 n = 102 — — Interviews with cases in 
stages I–Iv  
Authors observed that 
women with less education 
lack awareness regarding 
the disease, resources, and 
treatments, and are not as 
proactive about seeking 
medical care
Grunfeld et al22 n = 30 oncologists — — Surveyed for stage Iv 
  treatment only  
Authors reported that 13.8% 
of clinicians rated education 
level as quite or very 
important in decision to give 
palliative chemotherapy
Mitchell et al26 n = 682  
– 8th grade or less: n = 107  
– Some HS: n = 119  
– HS complete: n = 174  
– Some post-HS: n = 140  
– College degree: n = 142
Having less education was  
a significant predictor of  
belief in religious  
intervention in place of  
treatment (r2 = −0.19)
— Study interviewed  
cancer-free women about 
hypothetical breast cancer 
experience  
reported P-value 0.0001
Peele et al28 n = 386 Women with more years  
of education were more  
likely to receive  
chemotherapy
— Study included stages I−Iv 
reported P-value of 0.006
Language barriers
Ashing-Giwa et al12 n = 102 — — Interviews with cases in 
stages I–Iv Authors reported  
that language barriers 
prevented half of the Latinas 
and some of the monolingual  
Asian-Americans in their 
study from following and  
meeting the requirements  
for treatment-related  
financial assistance
Grunfeld et al22 n = 30 oncologists — — Surveyed for stage Iv 
treatment only  
Authors reported  
that 20.7% of clinicians rated 
language barriers as quite or 
very important in decision  
to give palliative 
  chemotherapy
Abbreviations: OR, odds ratio; CI, confidence interval; NR, not reported; BCS, breast-conserving surgery; SES, socioeconomic status; WHN, Women’s Health Network; HS, 
high school; MA, Massachusetts.International Journal of Women’s Health 2010:2 113
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and “concurrent medical conditions” were deemed “quite 
important” or “very important” to 93.1% and 82.8% of 
surveyed clinicians, respectively, compared to the 58.6% of 
oncologists who considered age to be of importance.22 Of the 
10 studies in this review citing the impact of age on chemo-
therapy use, only two adjusted for co-morbidities,17,18 one of 
which18 provided data specific to metastatic breast cancer. 
In both studies, multivariate analyses revealed a stronger 
inverse association of increasing age and chemotherapy use 
than that of co-morbidity and chemotherapy use. The higher 
prevalence of hormone receptor (estrogen-or progesterone-
receptor [ER/PR]) positive tumors among postmenopausal 
women than premenopausal women,32 and therefore more 
frequent use of hormone therapy, also contributes to this 
observation. It has been suggested that elderly patients have 
cancers with lower proliferative indices, and that they will 
derive less benefit from standard chemotherapy;33 however, 
the elderly are frequently underrepresented in cancer clinical 
trials. Although elderly (65 years of age or older) patients 
make up 63% of cancer patients in the US, they represent 
only 25% of the cancer clinical trial participants.34 Whether 
this deficit is due to fear and misunderstanding of older 
patients, physician bias against enrolling older patients, or 
overly stringent eligibility criteria that limit the number of 
elderly patients, their underrepresentation makes it difficult 
to assess the risks and benefits of cancer chemotherapeutic 
regimens and may partially explain the inverse relationship 
between age and chemotherapy use.
race
Five studies, all conducted in the United States, considered 
race to be a factor in predicting receipt of chemotherapy in 
breast cancer patients12,18,25,26,29 Only one study presented 
data specific to metastatic breast cancer,18 with the remain-
der considering all cases (stages I through IV) in aggregate. 
In Du and Goodwin,18 the proportions of black and white 
women with stage IV breast cancer who received chemo-
therapy were similar (26.8% versus 26.5%, respectively), 
although fewer women whose race was classified as “other” 
received chemotherapy (18.2%). Two other studies (not 
specific to stage IV disease) reported very small differences 
in the percentages of Caucasian, African-American, and 
Hispanic women with breast cancer treated with chemo-
therapy; both noted that higher proportions of Caucasian 
women (81.3%25 and 67.0%29) than African-American 
women (80.0%25 and 46.5%29) or Hispanic women (52.4%29) 
received chemotherapy, although these differences either 
were not statistically significant25 or statistical significance 
was not evaluated.29
A qualitative study interviewed women of different races 
and indicated that African-American women were the least 
likely to receive adjuvant therapies, including chemotherapy, 
and it was suggested that economic-related issues and insuf-
ficient insurance coverage might be the underlying reasons.12 
Two studies reported that African-American women were 
more likely to believe in alternative medicine or religious 
intervention in place of Western treatments.12,26 Only one 
study reported on Hispanic women. Similar to the age effect, 
the disparities in cancer care among ethnic minorities have 
been well documented in the literature.9,12,13,15 Treatment for 
ethnic minority groups may also be influenced by other fac-
tors that affect these groups, including socioeconomic issues, 
cultural beliefs, language barriers, challenges in access to 
care, and different rates of co-morbidities,35 making it difficult 
to determine the optimal method to address this disparity.
SeS/Income
Three studies discussed SES or income in relation to che-
motherapy treatment – two in the US12–24 and one in the 
UK16 – although none was specific to metastatic breast 
cancer. Of the two studies that provided numerical data, 
neither observed a significant difference in the proportions 
of patients receiving chemotherapy by income or SES,16–24 
although one suggested that their observation that uninsured, 
lower income women were less likely to receive chemo-
therapy may have reached statistical significance with a 
larger sample size.24 A qualitative study of community health 
professionals working with diverse populations reported that 
individuals with lower SES may lack awareness regarding the 
disease, resources, and treatments, and are not as proactive 
about seeking medical care.12
education
Four studies discussed education level in relation to che-
motherapy treatment,12,22,26,28 as well as other adjuvant 
therapies such as radiation and hormone therapy; only two 
provided quantitative data related to chemotherapy,26–28 
and only one was specific to metastatic breast cancer.22 
Peele and colleagues stated that educated women were 
significantly more likely to choose treatment with adju-
vant therapy, including chemotherapy, hormone therapy, 
and combination therapy, although the study did not 
distinguish between cases based on disease severity and 
treatment.28 Mitchell and colleagues reported that having 
less education was statistically significantly (P  0.0001) 
and inversely correlated with a belief in “religious inter-
vention in place of treatment”;26 it is presumed that the 
treatment likely included chemotherapy due to inclusion International Journal of Women’s Health 2010:2 114
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of women with advanced-stage breast cancer in the study 
population. Qualitatively, Ashing-Giwa and colleagues, 
when discussing various adjuvant therapies, including 
chemotherapy, reported that less-educated women in the 
United States were less informed about breast cancer itself, 
as well as resources and treatments, and were less proactive 
in seeking medical care.12 In the UK, 13.8% of clinicians 
ranked education as an important factor influencing their 
recommendation for palliative chemotherapy to women 
with metastatic breast cancer.22
Language barriers
Only two studies, both qualitative, discussed the effect 
of language barriers on the receipt of chemotherapy.12,22 
  Ashing-Giwa and colleagues reported that language barriers 
prevented half of the Latinas and some of the monolingual 
Asian-Americans in their study from following and meeting 
the requirements for treatment-related financial assistance,12 
while Grunfeld and colleagues reported that only 20.7% of 
surveyed UK clinicians felt that language barriers were an 
important factor in their decision to treat metastatic breast 
cancer with palliative chemotherapy.22
Hospital/physician/insurance 
characteristics
Four studies discussed differences in hospital, physician, or 
insurance status and their effect on the percentage of patients 
treated with chemotherapy19,23,24,28 (Table 2).
Insurance status
Two studies reported on insurance status.12–24 Liu and col-
leagues compared the proportion of women enrolled in the 
Women’s Health Network (WHN) – a National Breast and 
Cervical Cancer Early Detection Program for uninsured, 
lower income women – who were treated with chemotherapy 
to the treatment of all other breast cancer cases (not limited 
to metastatic disease) reported to the Massachusetts Cancer 
Registry (MCR).24 They found that similar proportions of 
women in the WHN and the MCR received chemotherapy 
(35.4% and 37.2%, respectively), with no statistically 
Table 2 Studies related to the role of hospital/physician/insurance characteristics in treatment decision making for breast cancer
Reference  Number of subjects  
in study
Percent of patients  
receiving chemotherapy
Comment 
Insurance status
Liu et al24 WHN: n = 331 (lower income)  
Other in MA state: n = 13,372
Uninsured: 35.4  
Insured: 37.2
Study included stages I–Iv 
Numbers also reported under  
SeS/Income.  
reported P = 0.2
Medicare reimbursement rate
Jacobson et al23 n = 2,246 By Medicare reimbursement index:  
Average: 25  
Plus 1 standard deviation: 26.1
Study included only stage Iv
Type of physician
Freyer et al19 n = 1,009  
– 65–74: n = 500  
– 75: n = 509
— Study included stage Iv only  
Treatment chosen by a single  
physician 65–74 years: 30%  
75 years: 43%
Percentage of physician type  
participating in therapeutic decision 
(65–74 year age group,  
75 year age group):  
Medical oncologists: 52%, 46%  
radiotherapists: 34%, 32%  
Surgeons: 22%, 14%  
Gynecologists: 18%, 14%  
General practitioners: 4%, 4%  
Gerontologists: 2%, 0%
Type of practice
Peele et al28 n = 386 Patients treated at university-based  
clinics were more likely to choose  
chemotherapy treatment
Study included stages I–Iv  
reported P0.01
Abbreviations: Or, odds ratio; Nr, not reported; WHN, Women’s Health Network; SeS, socioeconomic status; MA, Massachusetts.International Journal of Women’s Health 2010:2 115
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  significant differences; however, the very existence of the 
WHN likely increased the treatment percentages for unin-
sured women, indicating that this study does not preclude 
the role of insurance status in determining the rate of women 
receiving chemotherapy. In their qualitative study of the use 
of adjuvant therapies, including chemotherapy, in women 
with all stages of breast cancer in aggregate, Ashing-Giwa 
and colleagues supported the suggestion that uninsured 
individuals are less likely to seek medical care.12
Medicare reimbursement rates
In the only study identified in this category, Jacobson and col-
leagues found that the index of excess Medicare reimburse-
ment had a minimal effect on the overall rate of chemotherapy 
treatment in cases with metastatic breast cancer, but did find 
that more generously reimbursed providers were more likely 
to choose more expensive chemotherapy regimens.23
Physician type
In a prospective survey of French specialists, including 
oncologists, radiotherapists, gynecologists, and internists, 
1,009 patients with metastatic breast cancer aged 65 to 
74 years and greater than 75 years old were evaluated.19 
Results indicated that physician type played a role in treat-
ment decision-making, with treatment chosen by a single 
physician—rather than in consultation—in 30% of cases in 
the younger age group and in 43% of patients in the older 
group. Freyer and colleagues noted that geriatricians were 
involved in only 2% of treatment discussions in the older 
patients.19 This difference was proposed as a possible fac-
tor underlying the observed substandard treatment of older 
women with breast cancer.
Type of practice
Peele et al reported that women attending university-based 
practices were significantly more likely (P  0.01) to choose 
adjuvant therapy,28 including chemotherapy, hormone 
therapy, and combination therapy. No other studies were 
identified that discussed practice type.
Clinical characteristics
Tumor characteristics and disease severity were the most 
frequently discussed clinical factors, considered in five 
of the seven studies identified in this category17,18,20,22,28 
(Table 3). The patient’s general health and co-morbidities 
were mentioned in four studies,14,18,19,22 and previous can-
cer treatments were mentioned in two studies.18,22 Three 
studies in this category were specific to metastatic breast 
cancer.18,19,22
Tumor characteristics/disease severity
Studies have demonstrated that chemotherapy is the 
preferred treatment in achieving pathologically complete 
remission in cases that are ER- and/or PR-negative,36 while 
hormonal and endocrine therapies may be more effective 
in the treatment of hormone receptor-positive disease.37 
Accordingly, general clinical reviews indicated that che-
motherapy should be used as the initial treatment in cases 
that are hormone receptor-negative37 and as treatment for 
ER/PR-positive advanced breast cancer that is refractory 
to hormonal therapy.38 The results of two analyses of the 
SEER–Medicare linked database may reflect these recom-
mendations. In Du and Goodwin,17 patients with ER-negative 
disease (and positive lymph node status) were 425% more 
likely to receive chemotherapy than those with ER-positive 
disease. In another publication by Du and Goodwin,18 
the overall proportion of breast cancer patients receiving 
  chemotherapy was 69.9% and 48.4% for women with node-
positive/ER-negative tumors (age groups 65–69 and older 
than 65 years, respectively), while only 4.8% and 2.9% of 
women with node-negative/ER-positive disease received 
chemotherapy (age groups 65–69 and older than 65 years, 
respectively); however, neither study was specific to meta-
static breast cancer for this particular factor.
Women with more severe disease (defined as having 
larger tumors, hormone-receptive negative disease, and 
node-positive disease) were more likely to undergo chemo-
therapy,17,18,20,28 especially when thoroughly informed about 
their treatment options through a decision aid, compared 
to a control pamphlet, in one trial (P = 0.04).28 The clinical 
characteristics most frequently cited as being important in 
clinicians’ decisions to recommend palliative chemotherapy 
were the pace of disease progression (89.7%) and site of 
metastases (79.3%), with tumor histologic type/grade cited 
less frequently as important to the decision-making process 
(24.1%). Other factors noted by more than half the clinicians 
as important included symptoms other than pain, concurrent 
medical conditions, site of metastases, toxicity with previ-
ous chemotherapy, pain, patient’s wishes, frailty, age, and 
social support.22
General health/co-morbidities
The subjective determination of the patient’s general 
health status was the most important criterion reported 
by clinicians for treatment with weaker doses of che-
motherapy in a French prospective study of metastatic 
breast cancer cases.19 Performance status of the patient 
was one of the most frequently cited influential factors International Journal of Women’s Health 2010:2 116
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Table 3 Studies related to the role of clinical characteristics in treatment decision making for breast cancer
Reference  Number of subjects  
in study
Percent of patients  
receiving chemotherapy
Odds ratio  Comment 
Tumor characteristics/disease severity
Du and Goodwin17 n = 10,604  
– Node+/er+: n = 1,741  
– Node+/er-: n = 335  
– Node+/er?: n = 418  
– Node-/er+: n = 3,879  
– Node-/er-: n = 689  
– Node-/er?: n = 1,319  
– Node unexamined: n = 2,223
Node positive,  
er negative:  
65−69 years: 69.9  
65+ years: 48.4  
Node negative,  
er positive:  
65−69 years: 4.8  
65+ years: 2.9
— Study included stages I–Iv
— Odds of receiving  
chemotherapy relative to  
a tumor size 1.0 cm:  
1.0−2.0 cm: 1.90  
(95% CI: 1.43−2.51)  
2.0−3.0 cm: 1.69  
(95% CI: 1.24−2.32)  
3.0−4.0 cm: 2.26  
(95% CI: 1.59−3.22)  
4.0+ cm: 2.16  
(95% CI: 1.52−3.06)  
Unknown: 2.98  
(95% CI: 1.99−4.50)
Study included stages I–Iv
Du and Goodwin18 n = 35,060 — Lymph node positive  
and er negative relative  
to lymph node positive  
and er positive:  
4.25 (95% CI: 2.69−4.89)  
Large relative to  
small tumor size:  
1.94 (95% CI: 1.61−2.34)  
Higher relative to  
lower stage:  
5.61 (95% CI: 4.54−6.92)
Study included stages I–Iv
Golledge et al20 n = 784 Lymph node positive: 25  
Lymph node negative: 9
— Study included stages I–Iv
Grunfeld et al22 n = 30 oncologists — — Surveyed for stage Iv  
treatment only  
Authors report that 27.6% of  
clinicians rated er/Pr  
status as quite or very  
important in decision to  
treat with palliative  
chemotherapy
Peele et al28 n = 386 Patients with more  
severe disease were  
more likely to choose  
chemotherapy treatment
— Study included stages I–Iv 
reported P-value 0.0001
Low severity with a  
decision aid: 58.3  
Low severity with a  
control pamphlet: 86.8  
High severity with a  
decision aid: 98.6  
High severity with a  
control pamphlet: 92.3
— Study included stages I–Iv  
reported P-values 0.003 for  
low severity and 0.04  
for high severity
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Table 3 (Continued )
Reference  Number of subjects  
in study
Percent of patients  
receiving chemotherapy
Odds ratio  Comment 
Patient health/comorbidities
Caban et al14 n = 234 Patients with disability: 13% 
Patients without  
disability: 29%
— Study includes stages I–Iv 
reported P-value 0.180  
Disabilities included those 
that limited the patient’s 
mobility and ability to lie flat 
and limitations of joint  
mobility that prevented 
abduction of the shoulder
Du and  
Goodwin17
n = 10,604  
– no comorbidity  
   claims: n = 312  
– 0 comorbidities: n = 8,160  
– 1 comorbidity: n = 815  
– 2 comorbidities: n = 372  
– 3+ comorbidities: n = 945
— Odds of receiving  
chemotherapy relative to a 
comorbidity index of 0:  
No comorbidity claims:  
0.68 (95% CI: 0.41−1.12)  
Comorbidity index 1: 0.80  
(95% CI: 0.59−1.07)  
Comorbidity index 2: 0.46  
(95% CI: 0.27−0.76)  
Comorbidity index 3+: 0.94  
(95% CI: 0.77−1.16)
Study includes stages I–Iv
Freyer et al19 n = 1,009 — — Study includes stage Iv only  
Physicians indicated that  
subjective determination of  
general health status was the  
most important criterion for  
treatment with weaker doses 
of chemotherapy
Grunfeld et al22 n = 30 oncologists — — Surveyed for stage Iv 
treatment only  
Percent of clinicians rating 
factor as quite or very 
important in decision to treat 
with palliative chemotherapy: 
Performance status: 96.6% 
Concurrent medical condi-
tions: 82.8% Frailty: 93.1%
Previous treatment
Du and Goodwin17 n = 10,604  
– No surgery: n = 291  
– BCS only: n = 1,446  
– BCS and rT: n = 2,236  
– Mastectomy only: n = 6,131  
– Mastectomy and rT: n = 500
 
No surgery: 27.2  
BCS only: 37.5  
BCS and rT: 23.1  
Mastectomy only: 19.4  
Mastectomy and  
radiotherapy: 30.2
— Information is specific to 
stage Iv
— Odds of receiving  
chemotherapy relative to  
no surgery as previous  
treatment:  
BCS only: 0.95  
(95% CI: 0.63−1.45)  
BCS and radiotherapy: 0.63  
(95% CI: 0.41−0.96)  
Mastectomy only: 0.83  
(95% CI: 0.55−1.25)  
Mastectomy and radiotherapy: 
0.92 (95% CI: 0.60−1.43)
Information includes stages  
I−Iv
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Table 3 (Continued )
Reference  Number of subjects  
in study
Percent of patients  
receiving chemotherapy
Odds ratio  Comment 
Grunfeld et al22 n = 30 oncologists — — Surveyed stage Iv treatment 
only. Percent of clinicians 
rating factor as quite or very 
important in decision to treat 
with palliative chemotherapy: 
Previous response to  
chemo: 86.2%  
Toxicity w/previous che-
motherapy: 79.3% Previ-
ous response to hormone 
therapy: 37.9%
Abbreviations: OR, odds ratio; CI, confidence interval; NR, not reported; BCS, breast-conserving surgery; ER, estrogen-receptor; PR, progesterone-receptor; RT, radiotherapy
(96.6%) in recommending palliative chemotherapy among 
UK clinicians.22 Other factors relating to patient health 
were also considered important, with 93.1% and 82.8%, 
respectively, agreeing that patient frailty and concurrent 
medical conditions were important. One study of breast 
cancer cases reported a statistically significantly lower 
probability of receiving chemotherapy for women with a   
co-morbidity index of two, compared to those with a   
co-morbidity index of 0 (OR = 0.46; 95% CI: 0.27–0.76), 
although this inverse relationship was not statistically 
significant among patients with a co-morbidity index 
of 3 or greater.18 Caban and colleagues did not find a 
significant difference in the rate of neoadjuvant chemo-
therapy treatment based on patient disabilities that limited 
mobility.14 While effects of specific co-morbidities may 
vary, the current studies indicate that overall health is an 
important factor in predicting receipt of chemotherapy 
for breast cancer.
Previous cancer treatments
Du and Goodwin provide data on the proportion of women 
with metastatic breast cancer who received chemotherapy 
according to their previous breast cancer treatments.18 The 
rates ranged from 19.4% (in those previously treated with 
mastectomy only) to 30.2% (in those previously treated 
with mastectomy and radiotherapy), although the authors 
did not report whether the difference was significant and 
did not indicate any clear trend, making it difficult to draw 
any conclusions from these data. Grunfeld and colleagues22 
cited “toxicity with previous chemotherapy” and “previ-
ous response to chemotherapy” as important factors in the 
decision to treat metastatic breast cancer with palliative 
chemotherapy by 79.3% and 86.2% of surveyed clinicians, 
respectively.
Psychosocial characteristics
Psychosocial characteristics studied in relation to receipt 
of chemotherapy for breast cancer included the presence of 
social partners or support,18,22,27 mental health,21,22 and the 
attempt to minimize the psychosocial impact of cancer on 
social, work, and family lives13 (Table 4).
Social support/partners
Two studies provided numerical data regarding the impact of 
a spouse or significant other on the receipt of chemotherapy 
treatment,18,27 one of which provided data specific to meta-
static breast cancer.18 Osborne and colleagues and Du and 
Goodwin reported that married women were more likely to 
receive chemotherapy than unmarried women (married = 
12.3% versus unmarried = 9.1%; 27 married = 37.4% versus 
unmarried = 20.7%18). One study suggested that unmarried 
women might receive chemotherapy less often due to patients’ 
personal concerns over postoperative assistance and transpor-
tation or the amount of out-of-pocket expense for treatment, 
or due to a doctor’s decision not to discuss such treatment 
options because of these assumptions.27 Of British clinicians 
surveyed, 51.7% reported that the patient’s social support 
was an important factor in their decision to give palliative 
chemotherapy to women with metastatic breast cancer.22
Mental health
In an analysis of the SEER–Medicare linked database, the 
authors reported that, among women whose breast cancer was 
stage IV at diagnosis, breast cancer cases with a prior diagnosis 
of depression were less likely to receive chemotherapy than 
were women without a prior diagnosis of depression (34.1% 
[nondepressed] versus 18.6% [depressed]; P  0.001).21 In 
a British survey, 44.8% of clinicians reported that a patient’s 
anxiety and depression were “quite important” or “very International Journal of Women’s Health 2010:2 119
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Table 4 Studies related to the role of psychosocial characteristics in treatment decision making for breast cancer
Reference  Number of subjects  
in study
Percent of patients  
receiving chemotherapy
Odds ratio  Comment 
Social partner/social support
Du and Goodwin17 n = 10,604  
– Married: n = 4,368  
– Unmarried: n = 5,937  
– Unknown: n = 299
Married: 37.4  
Unmarried: 20.7  
Unknown: 18.8
— Information is specific  
to stage Iv disease
— Odds of receiving  
chemotherapy  
relative to married 
patients:  
Unmarried: 0.81  
(95% CI: 0.70−0.94) 
Unknown: 0.68  
(95% CI: 0.42−1.10)
Information includes  
stages I−Iv
Grunfeld et al22 n = 30 oncologists — — Surveyed for stage Iv  
treatment only.  
Authors report that 51.7% of 
clinicians rated social support 
as quite or very important in 
the decision to treat with  
palliative chemotherapy
Osborne et al27 n = 32,268  
– Married: n = 14,247  
– Unmarried: n = 18,021
Married: 12.3  
Unmarried: 9.1
— Study included stages I–Iv  
reported P-value 0.001
Mental health
Goodwin et al21 n = 24,696  
– Depressed: n = 1,841  
– Nondepressed: n = 22,855
Depressed: 18.6  
Nondepressed: 34.1
— Study included only  
stage Iv cases  
reported p-value 0.0142
Grunfeld et al22 n = 30 oncologists — — Surveyed for stage Iv  
treatment only. Percent of 
clinicians rating factor as quite 
or very important in decision 
to treat with palliative chemo-
therapy: Anxiety: 44.8%  
Depression: 44.8%  
Pre-morbid  
personality: 27.6%
Psychosocial impact minimization
Butow et al13 n = 99  
(minimizers defined  
as those who scored  
above median, nonminimizers  
were those who scored at  
or below median)
Patient attempted to  
minimize impact on  
social, work, and family  
life, percent that received  
chemotherapy:  
Yes: 22.0  
No: 55.0
— Study included only stage Iv  
reported P-value 0.001
Patient/family wishes
Grunfeld et al22 n = 30 oncologists — — Surveyed for stage Iv  
treatment only  
Percent of clinicians rating fac-
tor as quite or very important   
in decision to treat with  
palliative chemotherapy:  
Patient’s wishes: 96.6%  
Patient’s family’s wishes: 37.9%
Abbreviations: OR, odds ratio; CI, confidence interval; NR, not reported.International Journal of Women’s Health 2010:2 120
Morimoto et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
important” in their decision to give palliative chemotherapy to 
patients with metastatic breast cancer, although only 27.7% felt 
that the patient’s pre-morbid personality was important.22
Psychosocial impact minimization
Butow and colleagues reported that Australian women 
with metastatic breast cancer who were attempting to mini-
mize the impact of their disease on their social, work, and 
family life (termed “minimizers”) were significantly less 
likely to receive chemotherapy than those who were not 
minimizing the impact of the disease (“nonminimizers”) 13. 
  Specifically, 55% of nonminimizers received chemotherapy, 
a statistically significant difference compared to minimizers 
(P  0.001).
Patient/family wishes
Grunfeld and colleagues reported that 96.6% of British 
clinicians considered the desire of the patient to continue 
treatment an important factor in their decision to recommend 
palliative treatment for metastatic breast cancer.22 The wishes 
of the patient’s family were reported to be influential to a 
lower proportion of clinicians (37.9%).22
Discussion
In this review of literature describing factors associated with 
receipt of chemotherapy among women with breast cancer, 
we found that women receiving chemotherapy tended to 
be younger, healthier, more frequently Caucasian, and of 
higher educational status, and had clinical characteristics 
of more severe disease, such as ER/PR-negative tumors. 
There was some evidence that the type of physician and 
attending a university-based facility were related to more 
frequent use of chemotherapy. Women with emotional/men-
tal health issues and less social support were less likely to 
receive chemotherapy, although these observations need to 
be replicated in additional studies to determine whether they 
constitute consistent trends. There was less evidence that fac-
tors such as income, insurance characteristics, or Medicare 
reimbursement rates had substantive influence on whether 
chemotherapy was used, with sometimes only a single study 
discussing these factors.
Only six of the 19 studies focused on women with meta-
static breast cancer, with the remaining studies analyzing 
cases of stage IV breast cancer in combination with all other 
stages of breast cancer. Typically, only a small percentage 
of the aggregated cases had metastatic disease. As noted 
earlier, the emphasis on palliative, rather than curative, 
treatment for those with metastatic disease would most 
likely influence differences in treatment patterns. However, 
a qualitative review of these studies reporting specifically 
on metastatic breast cancer compared to those evaluating all 
cases in aggregate revealed no striking differences in factors 
affecting treatment receipt across stage, suggesting that the 
factors listed above are likely important for women with both 
early- and late-stage disease.
The patterns of chemotherapy use observed in this review 
appear to largely reflect a few general underlying influences. 
The lack of chemotherapy for older women is important, 
because breast cancer incidence and mortality rates peak in 
the elderly,2 and the population of elderly women in the US 
is growing rapidly.39 The conservative use of chemotherapy 
in the elderly has been reported consistently for several other 
cancer types.40–43 Older age and multimorbidity are often 
intertwined as co-morbidities increase with advancing age, 
which may limit treatment options.44,45 The less frequent use 
among older women and women with lower general health 
status and higher numbers of co-morbidities may also reflect 
lack of evidence of efficacy, because these women are typi-
cally underrepresented in clinical trials. It is also possible 
that, because the proportion of ER-positive tumors increases 
with age,46 the less frequent use of chemotherapy among older 
women reflects the shift from cytotoxic regimens to hormonal 
therapies, as per current clinical guidelines for treatment of 
hormone receptor-positive tumors.6,44
The less frequent use of chemotherapy among ethnic/
racial minorities, and women of lower educational attain-
ment, is consistent with the results of other studies of health 
disparities in cancer outcomes and treatment, as well as other 
diseases, and most likely reflects limitations in access to care 
and unawareness of treatment options.35,47 The decreased 
chemotherapy use among women with emotional and mental 
health issues may reflect the recognition on the part of the 
treating physician, and possibly the patient herself, of the 
trade-offs between quantity of life gained and quality of life 
lost at this juncture.7
There are a few important limitations to consider when 
interpreting these results. In addition to the relative paucity 
of studies examining factors that affect receipt of chemo-
therapy, with only 19 studies identified since 2000, no study 
attempted to thoroughly dissect the many potential factors 
that may be involved. Most studies considered only one or 
two factors, and as such, were unable to adjust for correla-
tions and potentially confounding effects, possibly creating 
spurious relationships and/or obscuring true ones. This 
could have considerable effects on conclusions derived from 
observational and other epidemiologic studies, as well as International Journal of Women’s Health 2010:2 121
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outcomes research. It is also likely that several other factors 
not reported in these papers may play an important role in the 
decision to treat metastatic breast cancer with chemotherapy 
or discussed factors that did not fall into the four categories 
of interest. Therefore, comprehensive studies examining these 
interrelated factors are needed to better understand the factors 
associated with receiving chemotherapy for metastatic breast 
cancer. Finally, because the study designs, the populations 
studied, and the measures of association varied so much 
across studies, summary measures could not be calculated, 
and results reflect a more qualitative than quantitative review 
of the literature.
Studying the patient, insurance/provider, and psychosocial 
factors associated with receipt of chemotherapy among breast 
cancer patients can provide a real-world view of usage patterns 
of treatment in clinical practice. While it is apparent that a 
combination of clinical guidelines, possible social disparities 
in health care, and personal  decision-making styles and beliefs 
among patients and their providers play a role in chemotherapy 
use, the current body of literature does not allow quantitative 
comparisons and assessments of the relative contributions of 
each selective factor. This review highlights the paucity of 
quantitative literature available with which to study the impact 
of these factors, both individually and as interrelated variables 
that inevitably impact each other. Future studies examining these 
patterns can aid patients and care providers when interpreting 
the clinical literature and making decisions about best course of 
treatment. Differential patterns of care can also provide guidance 
to policy makers when developing programs and interventions 
to reduce disparities in health care access.
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